Platelet‑rich plasma shows beneficial effects for patients with knee osteoarthritis by suppressing inflammatory factors

Abstract

Abstract. Knee osteoarthritis is a degenerative disease that may develop due ageing, obesity, strain, congenital abnormal joints, joint deformity or trauma. It is caused by many factors, such as degradation of articular cartilage injury, joint edge and subchondral bone hyperplasia of reactivity. Platelet-rich plasma (PRP) is an autologous blood sample that contains highly concentrated platelets and multiple cell growth factors. PRP promotes synovial cell proliferation and differentiation and may recover cartilage morphology. In the present study, the clinical efficacy of PRP was investigated in patients with knee osteoarthritis aged between 18 and 30 years in a phase-III clinical study. Following an 8-week baseline, patients with knee osteoarthritis were randomized into once-weekly, double-blind treatment with PRP (2-14 ml) or placebo groups. The results indicated that patients with osteoarthritis treated with PRP had modulated plasma concentrations of inflammatory factors and pro-angiogenic factors compared with the placebo group. Treatment responses were assessed by median percent reduction in inflammatory and pro-angiogenic factors and these improved with PRP treatment compared with the placebo. Clinical data indicated that PRP alleviated knee osteoarthritis and reduced humoral and cellular immune responses that led to beneficial effects on histological parameters. Inflammation was significantly alleviated in patients receiving PRP compared with the placebo group. The most common treatment-emergent adverse events in the presence of PRP were hypertension and proteinuria. In conclusion, treatment with PRP for patients with knee osteoarthritis presented beneficial effects in alleviating joint inflammation, cartilage destruction and bone damage, and repairing joint tissue. These results suggested that PRP may be a potential therapeutic agent for knee osteoarthritis.

Assessments of Therapeutic Effects of Platelet-rich Plasma in Knee Osteoarthritis: Possible Role of Inflammatory Cytokines

“…While platelet-rich plasma (PRP) has been approved as an agent for knee osteoarthritis therapy, different studies of PRP in the OA knee have found more consistently positive results compared to hyaluronic acid, other intraarticular injections and placebo than in other musculoskeletal tissues [25,26]. Although the causes of osteoarthritis in the knee are not fully understood, laboratory and clinical evidence suggest that in ammatory cytokines can contribute to its pathogenesis [27,28].…”

An injectable platelet lysate-hyaluronic acid hydrogel supports cellular activities and induces chondrogenesis of encapsulated mesenchymal stem cells

“…As a new therapy for osteoarthritis (OA), autologous platelet rich plasma (PRP) was injected in the knee joint 2 or 3 times weekly [41,42]. Preliminary results indicated that PRP is safe and can reduce pain and improve joint function [43][44][45][46]. However, despite the promising findings, the efficacy of using PRP for treat-ing cartilage defect has remained controversial [47][48][49].…”

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

“…Huang et al, upon studying the effectiveness of knee intra‐articular therapy with PRP, observed reductions in plasma levels of inflammatory ILs, including IL‐17A, IL‐1β, RANKL, IL‐6 and IFN‐γ, and increased levels of GFs, such as hepatocyte GF, intercellular adhesion molecule 1, osteopontin, platelet‐derived endothelial cell GF, vascular endothelial GF, platelet‐derived GF, insulin‐like GF 1, and transforming GF‐β. Several of these ILs and GFs are also involved in the embryonic implantation process 35 …”